Drugs@FDA document
ZERBAXA Letter · NDA 206829 SUPPL-12
Drugs@FDA document · CUBIST PHARMS LLC · Apr 22, 2022
Key facts
| Drug name | ZERBAXA |
|---|---|
| Document type | Letter |
| Application | NDA206829 |
| Submission | SUPPL-12 |
| Company | CUBIST PHARMS LLC |
| Document date | Apr 22, 2022 |
At a glance
- Efficacy-New Patient Population Document categories
- 10–99 Documents for this application
- 10–99 USP chapters cited in this application's documents
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About Drugs@FDA documents
Drugs@FDA posts the letters, labels, reviews and other documents behind each drug application and supplement. Orca1 indexes every document's full text and flags complete response letters.
Source: U.S. Food and Drug Administration (FDA), Drugs@FDA application documents · Source date: